About
Sanoculis Ltd. is an Israeli startup dedicated to ophthalmic medical device technology, specializing in minimally invasive surgical solutions for glaucoma treatment. The company has developed the MIMS® (Minimally Invasive Micro Sclerostomy) system, a stent-less device designed to lower intraocular pressure during glaucoma surgeries. MIMS® is CE marked and has been used in the treatment of over 110 patients. Additionally, Sanoculis offers the MINT® (Minimally Invasive Nasal Trabeculostomy) product, which has also received CE Mark approval. MINT® utilizes a semi-automated trephination technology to create openings in the trabecular meshwork, providing a less invasive treatment option for adult glaucoma patients. Clinical studies indicate that MINT® is effective in reducing intraocular pressure and minimizing the need for glaucoma medications. The company targets healthcare providers and ophthalmology specialists, aiming to enhance patient outcomes and streamline surgical procedures. Sanoculis collaborates with Appasamy, India's largest ophthalmic equipment manufacturer, to distribute its products in the Indian market. The company is based in Tel Aviv and is actively seeking further regulatory approvals to expand its global presence.
Technologies
Keywords
Company Information
-
Employees 9
-
Founded 2012
-
Annual Revenue $1200000
Location
8 Ландау, Kiryat Ono, Tel Aviv District, Israel, 5555108
